SFI and Pfizer announce biotherapeutic R&D programme for Ireland
18 April 2016
Funding awarded to researchers in Ireland to find potential new therapies for patients of unmet needs
Science Foundation Ireland (SFI) and Pfizer have announced the recipients of the 2016 SFI-Pfizer Biotherapeutics Innovation Award programme.
The collaboration between SFI and Pfizer provides qualified academic researchers with an opportunity to deliver important potential discoveries in the areas of immunology, oncology, cardiovascular and rare diseases.
The biotherapeutics innovation programme has awarded funding to researchers from across three academic institutions in Ireland including the Royal College Surgeons (RCSI), University College Cork (UCC) and University College Dublin (UCD).
In addition to the funding, academic researchers will have the unique opportunity to work with the Pfizer Global Biotherapeutics Technology (GBT) group, at Grangecastle in Dublin, as well as Pfizer’s R&D innovation engine, the Centers for Therapeutic Innovation. The teams’ research will focus on the application of cutting edge technologies for next generation protein therapies.
“We are delighted to continue this successful partnership with Pfizer to support innovative research and development that could help deliver significant advances in critical areas of medical need. The success of the award programme is a reflection of the quality and relevance of academic scientific research in Ireland – excellence and impact,” said Prof Mark Ferguson, director general of SFI.
“Pfizer are delighted with the continued collaboration with SFI. As an organisation we are focused on delivering innovative therapies that significantly improve patients’ lives and investment in early stage research is critical to achieving this,” said Dr Paul Duffy, vice president, biopharmaceutical operations and external supply, Pfizer.
“Collaborations between industry and academia remain key in helping to expedite the translation of scientific discoveries into breakthrough therapies that matter for patients in need,” he added.
In 2015, five proposals representing four institutions across Ireland were awarded similar funding. Over the past year the researchers have worked in collaboration with Pfizer colleagues on potential new therapies for diseases including haemophilia, fibrosis, motor neuron disease, psoriasis and Crohn’s disease. A number of these programmes are advancing and are on track to reaching their goals.
The recipients of the SFI-Pfizer Biotherapeutics Innovation Award are:
Prof Martin Steinhoff, University College Dublin – Prof Steinhoff leads a translational research team attempting to understand the molecular mechanisms underlying skin inflammation and associated chronic itch, for which there remains a significant unmet clinical need. The team hopes to generate targeting molecules that block the activation of key players in these inflammatory pathways.
Dr Anne Moore, University College Cork – The remit of Dr Moore’s group is to develop and translate innovative therapies that modulate immune function. Mounting evidence from recent clinical studies demonstrates that harnessing the body’s own immune response to kill tumour cells can be a very effective mechanism to treat cancer. This collaboration aims to develop a novel strategy that enhances the body’s natural anti-tumour response.
Dr Leonie Young and Prof Arnold Hill, Royal College of Surgeons of Ireland – Dr Young and Prof Arnold Hill are interested in the underlying mechanisms that control breast cancer resistance to traditional chemotherapeutics. Their aim is to use pre-clinical models, clinical datasets and breast cancer patient samples to better characterize, and effectively target, treatment resistant breast cancers.http://www.engineersjournal.ie/2016/04/18/sfi-and-pfizer-announce-rd-programme-for-ireland/http://www.engineersjournal.ie/wp-content/uploads/2016/04/SFI-Pfizer-1024x683.jpghttp://www.engineersjournal.ie/wp-content/uploads/2016/04/SFI-Pfizer-300x300.jpgNewsawards,biomedical,Ireland,medical devices,Pfizer,SFI